Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

The impact of systems approaches on biological problems in drug discovery

Nature Biotechnology volume 22, pages 1215–1217 (2004)Cite this article

The production of new molecular entities (NMEs) endowed with salutary medicinal properties provides a key metric by which the effectiveness of the pharmaceutical industry may be judged. Nearly a decade ago, Jürgen Drews1 noted that the combined output of NMEs by all major pharmaceutical companies at the time was insufficient to support the healthy growth of the group. Indeed, a recent analysis documents a 30-year decline in pharmaceutical R&D productivity2. This decline in productivity has occurred despite accelerating investment in biomedical research on the part of both industry and governments, with compound annual growth rates in research expenditures approaching 13% (ref. 2). Approvals aside, the number of late-stage clinical trials supported by the pharmaceutical industry has also declined during the past decade3, auguring poorly for future triumphs in disease interdiction. Despite several notable discoveries, the emergence of major biotech companies has done little to improve the yield of new disease-ameliorating molecules.

How is it that extraordinary advances in biomedical research over the past decade have exerted so little positive effect on drug discovery? We argue here that an inability to visualize the complexity of biological systems has impeded the identification of novel therapies. In the future, application of systems approaches to drug discovery promises to have a profound impact on medical practice, permitting a comprehensive evaluation of underlying predisposition to disease, disease diagnosis and disease progression. In the near term, systems biology will provide powerful means for validating new drug targets, improving the success with which pharmaceuticals are identified. Farther into the future, the same approaches will drive the development of early diagnostics, enabling disease stratification, individualized therapy and ultimately preventive drugs, based on both genetic and environmental considerations. Although systems biology as currently envisioned does not have a direct impact on the chemistry of identifying drugs or pharmacological challenges of drug metabolism, it may provide rapid and useful assays for these in the future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Research and development expenditures in the pharmaceutical industry.

Bob Crimi

References

  1. Drews, J. Nat. Biotechnol. 14, 1516–1518 (1996).

    Article  CAS  Google Scholar 

  2. Booth, B. & Zemmel, R. Nat. Rev. Drug Disc. 3, 451–456 (2004).

    Article  CAS  Google Scholar 

  3. Anonymous. Parexel's Pharmaceutical R&D Statistical Sourcebook 2003/2004, p. 42 (Parexel International Corporation, Waltham, MA, 2003).

  4. Weston, A.D. & Hood, L. J. Proteome Res. 3, 179–196 (2004).

    Article  CAS  Google Scholar 

  5. Weston, A.D., Baliga, N.S., Bonneau, R. & Hood, L. in The Genome of Homo Sapiens, Volume LXVIII, Symposia on Quantitative Biology, 345–357 (Cold Spring Harbor Press, Cold Spring Harbor, NY, 2004).

    Google Scholar 

  6. Kunkel, E.J. et al. FASEB J. 18, 1279–1281 (2004).

    Article  CAS  Google Scholar 

  7. Nicholson, J.K. & Wilson, I.D. Nat. Rev. Drug. Discov. 2, 668–676 (2003).

    Article  CAS  Google Scholar 

  8. Paez, J.G. et al. Science 304, 1497–1500 (2004).

    Article  CAS  Google Scholar 

  9. Lynch, T.J. et al. N. Eng. J. Med. 350, 2129–2139 (2004).

    Article  CAS  Google Scholar 

  10. Drug Week, Pharmaceutical Development, 25 June 2004. http://www.NewsRx.com/

  11. Pharmaceutical Industry Profile 2004 (Pharmaceutical Research and Manufacturers of America, Washington, DC, 2004). http://www.phrma.org/publications/publications//2004-03-31.937.pdf

Download references

Author information

Authors and Affiliations

  1. the Institute for Systems Biology, 1441 North 34th Street, Seattle, 98103-8904, Washington, USA

    Leroy Hood

  2. Amgen, Inc., One Amgen Center Drive, Thousand Oaks, 91320-1799, CA, USA

    Roger M Perlmutter

Authors
  1. Leroy Hood
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roger M Perlmutter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hood, L., Perlmutter, R. The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol 22, 1215–1217 (2004). https://doi.org/10.1038/nbt1004-1215

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1004-1215

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing